TABLE 4.

Characteristics of case reports studies reporting CR bacteria in HM patients.

	Study	Place	Year	Age (Y)	Hematologic malignancies	Other conditions	Therapeutic antiobiotic administrated	CR Species	Sites of isolation	Resistance mecanisms	Antimicrobial susceptibility	Death
Asia	(Asai et al., 2018) Infectious Diseases in Clinical Practice	Japan	NA	55	AML	neutropenia 5 days after HSCT	tigecycline	Kp	stool, blood	blaDHA–1 and Plasmid FIA(HI1)	tigecycline, colistin	Yes
	(Huang et al., 2015) Ann Clin Microbiol Antimicrob	China	2014	30	ALL	previous exposure to colistin	NA	E. cloacae	blood	IMI-1 variant	ceftazidime, amikacin, ciprofloxacin, tigecycline, aztreonam, ceftriaxone, cefepime, piperacillin–tazobactam, gentamicin, tobramycin, levofloxacin, trimethoprim, minocycline	NA
	(Zhang et al., 2018) Emerging Microbes and Infections	China	2014–2017	29	AML monocytic	NA	meropenem, isepamicin, vancomycin, teicoplanin, piperacillin-sulbactam, tigecycline, fosfomycin, amikacin, colistin, linezolid, polymyxin B	Kp (17 isolates)	fecal, blood, sputum	KPC-2	tigecycline in strains 1 to 8, colistin in strain 1 to 9	No
	(Zhang et al., 2016) IJID	China	2014	56; 22; 63	AL	imipenem and vancomycin prophylaxis	NA	E. coli	blood	NDM-5	NA	NA
	(Xing et al., 2015) Internal Medicine	China	2014–2016	40; 54; 59; 58; 44	T natural killer (NK) lymphoma, B lymphoma, ALL, AML, AA	1/5 agranulocytosis	Moxifloxacin–sulbactam/cefoperazone–tigecycline–fosfomycin–imipenem/cilastatin; meropenem–tigecycline; tigecycline–cefoperazone/sulbactam; moxifloxacin–amikacin; imipenem/cilastatin–vancomycin–tigecycline–amikacin–fosfomycin	Kp	4 blood, 1 sputum	KPC -2	100% tigecycline, 1/5 levofloxacin, 3/5 amiklin, 2/5 gentamicin, 2/5 vibramycin	4/5
Middel east	(Kantarcioglu et al., 2016) Molecular and Clinical Oncology	Turkey	2015	50	CML	prior hospitalization in Libya	tigecycline, meropenem, imipenem, gentamicin, sulbactam,	Kp	blood and valve	NA	tigecycline	No
	(Muchtar et al., 2012) IMAJ	Israel	2012	64	pro-B ALL	neutropenia	piperacillin/tazobactam, vancomycin, meropenem, tigecycline, rifampicin and amikacin	Kp	blood, skin abscess	NA	colistin, amikacin	Yes
Northern europe	(Majewski et al., 2017) IJID	Poland	2013	60	AML	neutropenia, trimethoprim and aciclovir prophylaxis	cefepime, amikacin, linezolid, teicoplanin, colistin, meropenem	C. freundii	urine	VIM-4	colistin	Yes
	(Leitner et al., 2014) AAC	Austria	2011-2013	[39-89]	7 AML, 2 B-cell NHL, 1 myelodysplasia	NA	NA	K. oxytoca	blood, skin, stool, urine, abscess, bronchoalveolar lavage, throat, swab	KPC-2	amikacin, colistin fosfomycin	4/11
Southern europe	(Carattoli et al., 2013) Euro Surv	Italy	2013	40	ALL	prior hospitalization in Belgrade	piperacillin/tazobactam, amikacin, vancomycin, meropenem, colistin, tigecycline, rifampicin, daptomycin	P. aeruginosa	perianal abscess, blood	NDM-1 ST235 strain	colistin	Yes
	(Piedra-Carrasco et al., 2017) Microbial Drug Resistance	Spain	2015	36	Myeloid sarcoma	ciprofloxacin prophylaxis	piperacillin/tazobactam, amikacin, double- carbapenem regimen ertapenem + imipenem	Kp	urine	KPC-3	gentamicin, colistin, tigecycline	No
America	(Satlin et al., 2013b) JCM	United States	NA	70	AML	neutropenia	piperacillin/tazobactam, vancomycin, meropenem, trimethoprim- sulfamethoxazole, linezolid, amikacin	E. gergoviae	blood	KPC-3	levofloxacin, gentamicin, amikacin, tigecycline	Yes
	(Chang et al., 2013) Rev Soc Bras Med Trop	Brazil	2010	94	CLL	NA	ciprofloxacin, piperacillin/tazobactam, vancomycin	Kp	Urine	KPC-2	cefoxitin, cefepime, colistin, tigecycline	Yes

AA, aplastic anemia; AL, acute leukemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CML, Chronic myeloid leukemia; Kp, Klebsiella pneumoniae; NHL, Non-Hodgkin’s lymphoma.